Nanoparticle formulations to enhance tumor targeting of poorly soluble polyphenols with potential anticancer properties

Seminars in Cancer Biology

Volumn 46, Issue , 2017, Pages 205-214

  Bonferoni, Maria Cristina ^a   Rossi, Silvia ^a   Sandri, Giuseppina ^a   Ferrari, Franca ^a  

^a UNIVERSITY OF PAVIA   (Italy)

Author keywords

Curcumin; Nanoparticles; Quercetin; Resveratrol; Tumor targeting

Indexed keywords

CURCUMIN; NANOPARTICLE; POLYPHENOL; QUERCETIN; RESVERATROL; STILBENE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; CANCER LOCALIZATION; CANCER PREVENTION; CANCER RESEARCH; DRUG ABSORPTION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG SOLUBILITY; DRUG STABILITY; HUMAN; HYDROPHOBICITY; NANOENCAPSULATION; NANOMEDICINE; NONHUMAN; REVIEW; TUMOR CELL; BIOAVAILABILITY; CHEMISTRY; NEOPLASM; PATHOLOGY;

BIOLOGICAL AVAILABILITY; CURCUMIN; DRUG COMPOUNDING; HUMANS; NANOPARTICLES; NEOPLASMS; POLYPHENOLS; QUERCETIN; STILBENES;

EID: 85021939821     PISSN: 1044579X     EISSN: 10963650     Source Type: Journal    
DOI: 10.1016/j.semcancer.2017.06.010     Document Type: Review

References (107)

1. Brglez Mojzer, E., Knez Hrncic, M., Škerget, M., Knez, Z., Bren, U., Polyphenols: extraction methods, antioxidative action, bioavailability and anticarcinogenic effects. Molecules, 21, 2016, 901, 10.3390/molecules21070901.
2. Tabrez, S., Priyadarshini, M., Urooj, M., Shakil, S., Ashraf, G.M., Khan, M.S., et al. Cancer chemoprevention by polyphenols and their potential application as nanomedicine. J. Environ. Sci. Health C Environ. Carcinog. Ecotoxicol. Rev. 31 (2013), 67–98, 10.1080/10590501.2013.763577.
3. Lambert, J.D., Elias, R.J., The antioxidant and pro-oxidant activities of green tea polyphenols: a role in cancer prevention. Arch. Biochem. Biophys. 501 (2010), 65–72, 10.1016/j.abb.2010.06.013.
4. Mileo, A.M., Miccadei, S., Polyphenols as modulator of oxidative stress in cancer disease: new therapeutic strategies. Oxid. Med. Cell Longev., 2016, 2016, 6475624, 10.1155/2016/6475624.
5. Manach, C., Scalbert, A., Morand, C., Rémésy, C., Jiménez, L., Polyphenols Food sources and bioavailability. Am. J. Clin. Nutr. 79 (2004), 727–747.
6. Mura, S., Couvreur, P., Nanotheranostics for personalized medicine. Adv. Drug Deliv. Rev. 64 (2012), 1394–1416, 10.1016/j.addr.2012.06.006.
7. Porcu, E.P., Salis, A., Gavini, E., Rassu, G., Maestri, M., Giunchedi, P., Indocyanine green delivery systems for tumour detection and treatments. Biotechnol. Adv. 34 (2016), 768–789, 10.1016/j.biotechadv.2016.04.001.
8. Giunchedi, P., Gavini, E., Dionigi, P., Maestri, M., Selective targeting of liver nodules: present situation and new challenges to enhance indocyanine green captation from colorectal liver metastases. Curr. Drug Deliv. 12 (2015), 474–476.
9. Matsumura, Y., Maeda, H., A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent SMANCS. Cancer Res. 46 (1986), 6387–6392.
10. Fang, J., Nakamura, H., Maeda, H., The EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv. Drug Deliv. Rev. 63 (2011), 136–151, 10.1016/j.addr.2010.04.009.
11. Fang, J., Sawa, T., Maeda, H., Factors and mechanism of EPR effect and the enhanced antitumor effects of macromolecular drugs including SMANCS. Adv. Exp. Med. Biol. 519 (2003), 29–49, 10.1007/0-306-47932-X_2.
12. Danhier, F., Feron, O., Préat, V., To exploit the tumor microenvironment: passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. J. Control. Release 148 (2010), 135–146, 10.1016/j.jconrel.2010.08.027.
13. Bertrand, N., Wu, J., Xu, X., Kamaly, N., Farokhzad, O.C., Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology. Adv. Drug Deliv. Rev. 66 (2014), 2–25.
14. Dreher, M.R., Liu, W., Michelich, C.R., Dewhirst, M.W., Yuan, F., Chilkoti, A., Tumor vascular permeability accumulation, and penetration of macromolecular drug carriers. J. Natl. Cancer Inst. 98 (2006), 335–344, 10.1093/jnci/djj070.
15. Alexandrakis, G., Brown, E.B., Tong, R.T., McKee, T.D., Campbell, R.B., Boucher, Y., et al. Two-photon fluorescence correlation microscopy reveals the two-phase nature of transport in tumors. Nat. Med. 10 (2004), 203–207, 10.1038/nm981.
16. Cabral, H., Matsumoto, Y., Mizuno, K., Chen, Q., Murakami, M., Kimura, M., et al. Accumulation of sub-100 nm polymeric micelles in poorly permeable tumours depends on size. Nat. Nanotechnol. 6 (2011), 815–823.
17. Albanese, A., Tang, P.S., Chan, W.C.W., The effect of nanoparticle size shape, and surface chemistry on biological systems. Annu. Rev. Biomed. Eng. 14 (2012), 1–16, 10.1146/annurev-bioeng-071811-150124.
18. Yang, B., Han, X., Ji, B., Lu, R., Competition between tumor and mononuclear phagocyte system causing the low tumor distribution of nanoparticles and strategies to improve tumor accumulation. Curr. Drug Deliv. 13 (2016), 1261–1274.
19. Li, J., Mao, H., Kawazoe, N., Chen, G., Insight into the interactions between nanoparticles and cells. Biomater. Sci. 5 (2017), 173–189, 10.1039/c6bm00714g.
20. Kulkarni, S., Feng, S.S., Effects of particle size and surface modification on cellular uptake and biodistribution of polymeric NPs for drug delivery. Pharm. Res. 30 (2013), 2512–2522.
21. Bareford, L.M., Swaan, P.W., Endocytic mechanisms for targeted drug delivery. Adv. Drug Deliv. Rev. 59 (2007), 748–758.
22. Yameen, B., Choi, W.I., Vilos, C., Swami, A., Shi, J., Farokhzad, O.C., Insight into nanoparticle cellular uptake and intracellular targeting. J. Control. Release 190 (2014), 485–499, 10.1016/j.jconrel.2014.06.038.
23. Rejman, J., Oberle, V., Zuhorn, I.S., Hoekstra, D., Size-dependent internalization of particles via the pathways of clathrinand caveolae-mediated endocytosis. Biochem. J 377 (2004), 159–169, 10.1042/BJ20031253.
24. Vasir, J.K., Labhasetwar, V., Quantification of the force of nanoparticle-cell membrane interactions and its influence on intracellular trafficking of nanoparticles. Biomaterials 29 (2008), 4244–4252, 10.1016/j.biomaterials.2008.07.020.
25. Kirpotin, D.B., Drummond, D.C., Shao, Y., Shalaby, R.M., Hong, K., Nielsen, U.B., et al. Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. Cancer Res. 66 (2006), 6732–6740.
26. Sun, L., Wu, Q., Peng, F., Liu, L., Gong, C., Strategies of polymeric nanoparticles for enhanced internalization in cancer therapy. Colloids Surf. B Biointerfaces 135 (2015), 56–72, 10.1016/j.colsurfb.2015.07.013.
27. Nag, M., Gajbhiye, V., Kesharwani, P., Jain, N.K., Transferrin functionalized chitosan-PEG nanoparticles for targeted delivery of paclitaxel to cancer cells. Colloids Surf. B Biointerfaces 148 (2016), 363–370, 10.1016/j.colsurfb.2016.08.059.
28. Zwicke, G.L., Mansoori, G.A., Jeffery, C.J., Utilizing the folate receptor for active targeting of cancer nanotherapeutics. Nano Rev., 3, 2012, 18496, 10.3402/nano.v3i0.18496.
29. Bahrami, B., Mohammadnia-Afrouzi, M., Bakhshaei, P., Yazdani, Y., Ghalamfarsa, G., Yousefi, M., et al. Folate-conjugated nanoparticles as a potent therapeutic approach in targeted cancer therapy. Tumor Biol. 36 (2015), 5727–5742, 10.1007/s13277-015-3706-6.
30. Colombo, M., Fiandra, L., Alessio, G., Mazzucchelli, S., Nebuloni, M., De Palma, C., et al. Tumour homing and therapeutic effect of colloidal nanoparticles depend on the number of attached antibodies. Nat. Commun., 7, 2016, 13818, 10.1038/ncomms13818.
31. Faridi, E.A., Jafari, S.M., Biopolymer nano-particles and natural nano-carriers for nano-encapsulation of phenolic compounds. Colloids Surf. B 146 (2016), 532–543, 10.1016/j.colsurfb.2016.06.053.
32. Ratnam, D.V., Ankola, D.D., Bhardwaj, V., Sahana, D.K., Kumar, M.N., Role of antioxidants in prophylaxis and therapy: a pharmaceutical perspective. J. Control. Release 113 (2006), 189–207, 10.1016/j.jconrel.2006.04.015.
33. Asensi, M., Medina, I., Ortega, A., Carretero, J., Bano, M.C., Obrador, E., et al. Inhibition of cancer growth by resveratrol is related to its low bioavailability. Free Radical Biol. Med. 33 (2002), 387–398.
34. Marier, J.F., Vachon, P., Gritsas, A., Zhang, J., Moreau, J.P., Ducharme, M.P., Metabolism and disposition of resveratrol in rats: extent of absorption, glucuronidation, and enterohepatic recirculation evidenced by a linked-rat model. J. Pharmacol. Exp. Ther. 302 (2002), 369–373, 10.1124/jpet.102.033340.
35. Wang, S., Su, R., Nie, S., Sun, M., Zhang, J., Wu, D., et al. Application of nanotechnology in improving bioavailability and bioactivity of diet-derived phytochemicals. J. Nutr. Biochem. 25 (2014), 363–376, 10.1016/j.jnutbio.2013.10.002.
36. Palange, A.L., Di Mascolo, D., Carallo, C., Gnasso, A., Decuzzi, P., Lipid-polymer nanoparticles encapsulating curcumin for modulating the vascular deposition of breast cancer cells. Nanomedicine 10 (2014), 991–1002, 10.1016/j.nano.2014.02.004.
37. Yallapu, M.M., Jaggi, M., Chauhan, S.C., Curcumin nanoformulations: a future nanomedicine for cancer. Drug Discov. Today 17 (2012), 71–80, 10.1016/j.drudis.2011.09.009.
38. Lee, W.H., Loo, C.Y., Young, P.M., Traini, D., Mason, R.S., Rohanizadeh, R., Recent advances in curcumin nanoformulation for cancer therapy. Expert Opin. Drug Deliv. 11 (2014), 1183–1201, 10.1517/17425247.2014.916686.
39. Nair, H.B., Sung, B., Yadav, V.R., Kannappan, R., Chaturvedi, M.M., Aggarwal, B.B., Delivery of antiinflammatory nutraceuticals by nanoparticles for the prevention and treatment of cancer. Biochem. Pharmacol. 80 (2010), 1833–1843, 10.1016/j.bcp.2010.07.021.
40. Beloqui, A., MÁ Solinís, Rodríguez-Gascón, A., Almeida, A.J., Préat, V., Nanostructured lipid carriers: promising drug delivery systems for future clinics. Nanomedicine 12 (2016), 143–161, 10.1016/j.nano.2015.09.004.
41. Rizwanullah, M., Ahmad, J., Amin, S., Nanostructured lipid carriers: a novel platform for chemotherapeutics. Curr. Drug Deliv. 13 (2016), 4–26, 10.2174/1567201812666150817124133.
42. Sun, M., Nie, S., Pan, X., Zhang, R., Fan, Z., Wang, S., Quercetin-nanostructured lipid carriers: characteristics andanti-breast cancer activities in vitro. Colloids Surf. B Biointerfaces 113 (2014), 15–24, 10.1016/j.colsurfb.2013.08.032.
43. Suksiriworapong, J., Phoca, K., Ngamsom, S., Sripha, K., Moongkarndi, P., Junyaprasert, V.B., Comparison of poly(e-caprolactone) chain lengths of poly(e-caprolactone)-co-d-a-tocopheryl-poly(ethylene glycol) 1000 succinate nanoparticles for enhancement of quercetin delivery to SKBR3 breast cancer cells. Eur. J. Pharm. Biopharm. 101 (2016), 15–24, 10.1016/j.ejpb.2016.01.008.
44. Mekaru, H., Lu, J., Tamanoi, F., Development of mesoporous silica-based nanoparticles with controlled release capability for cancer therap. Adv. Drug Deliv. Rev. 95 (2015), 40–49.
45. Yang, Y., Yu, C., Advances in silica based nanoparticles for targeted cancer therapy. Nanomedicine 12 (2016), 317–332, 10.1016/j.nano.2015.10.018.
46. Chou, C.C., Yang, J.S., Lu, H.F., Ip, S.W., Lo, C., Wu, C.C., et al. Quercetin-mediated cell cycle arrest and apoptosis involving activation of a caspase cascade through the mitochondrial pathway in human breast cancer MCF-7 cells. Arch. Pharm. Res. 33 (2010), 1181–1191.
47. Dai, W., Gao, Q., Qiu, J., Yuan, J., Wu, G., Shen, G., Quercetin induces apoptosis and enhances 5-FU therapeutic efficacy in hepatocellular carcinoma. Tumor Biol. 37 (2016), 6307–6313, 10.1007/s13277-015-4501-0.
48. Sarkar, A., Ghosh, S., Chowdhury, S., Pandey, B., Sil, P.C., Targeted delivery of quercetin loaded mesoporous silica nanoparticles to the breast cancer cells. Biochim. Biophys. Acta 1860 (2016), 2065–2075, 10.1016/j.bbagen.2016.07.001.
49. Kunjachan, S., Blau, A., Mockel, D., Theek, B., Kiessling, F., Etrych, T., et al. Overcoming cellular multidrug resistance using classical nanomedicine formulations. Eur. J. Pharm. Sci. 45 (2012), 421–428, 10.1016/j.ejps.2011.08.028.
50. Tan, B.J., Liu, Y., Chang, K.L., Lim, B.K., Chiu, G.N., Perorally active nanomicellar formulation of quercetin in the treatment of lung cancer. Int. J. Nanomed. 7 (2012), 651–661, 10.2147/IJN.S26538.
51. Zhao, J., Liu, J., Wei, T., Ma, X., Cheng, Q., Huo, S., et al. Quercetin-loaded nanomicelles to circumvent human castration-resistant prostate cancer in vitro and in vivo. Nanoscale 8 (2016), 5126–5138, 10.1039/C5NR08966b.
52. Gursoy, R.N., Benita, S., Self-emulsifying drug delivery systems (SEDDS) for improved oral delivery of lipophilic drugs. Biomed. Pharmacother. 58 (2004), 173–182.
53. Rahman, M.A., Harwansh, R., Mirza, M.A., Hussain, S., Hussain, A., Oral lipid based drug delivery system (LBDDS): formulation, characterization and application: a review. Curr. Drug Deliv. 8 (2011), 330–345.
54. Jain, A.K., Thanki, K., Jain, S., Novel self-nanoemulsifying formulation of quercetin: implications of pro-oxidant activity on the anticancer efficacy. Nanomedicine 10 (2014), 959–969, 10.1016/j.nano.2013.12.010.
55. Tripathi, S., Kushwah, V., Thanki, K., Jain, S., Triple antioxidant SNEDDS formulation with enhanced oral bioavailability: implication of chemoprevention of breast cancer. Nanomedicine 12 (2016), 1431–1443, 10.1016/j.nano.2016.03.003.
56. Mattheolabakis, G., Milane, L., Singh, A., Amiji, M.M., Hyaluronic acid targeting of CD44 for cancer therapy: from receptor biology to nanomedicine. J. Drug Target. 23 (2015), 605–618, 10.3109/1061186X.2015.
57. Kesharwani, P., Xie, L., Banerjee, S., Mao, G., Padhye, S., Sarkar, F.H., et al. Hyaluronic acid-conjugated polyamidoamine dendrimers for targeted delivery of 3,4-difluorobenzylidene curcumin to CD44 overexpressing pancreatic cancer cells. Colloids Surf. B Biointerfaces 136 (2015), 413–423, 10.1016/j.colsurfb.2015.09.043.
58. Pang, X., Lu, Z., Du, H., Yang, X., Zhai, G., Hyaluronic acid-quercetin conjugate micelles: synthesis, characterization, in vitro and in vivo evaluation. Colloids Surf. B Biointerfaces 123 (2014), 778–786, 10.1016/j.colsurfb.2014.10.025.
59. Vecchione, R., Quagliariello, V., Calabria, D., Calcagno, V., De Luca, E., Iaffaioli, R.V., et al. Curcumin bioavailability from oil in water nano-emulsions: in vitro and in vivo study on the dimensional, compositional and interactional dependence. J. Control. Release 233 (2016), 88–100, 10.1016/j.jconrel.2016.05.004.
60. Wan, K., Sun, L., Hu, X., Yan, Z., Zhang, Y., Zhang, X., Zhang, J., Novel nanoemulsion based lipid nanosystems for favorable in vitro and in vivo characteristics of curcumin. Int. J. Pharm. 504 (2016), 80–88, 10.1016/j.ijpharm.2016.03.055.
61. Kuo, Y.C., Liang, C.T., Inhibition of human brain malignant glioblastoma cells using carmustine-loaded catanionic solid lipid nanoparticles with surface anti-epithelial growth factor receptor. Biomaterials 32 (2011), 3340–3350.
62. Mauroy, C., Castagnos, P., Orio, J., Blache, M.C., Rico-Lattes, I., Teissié J., et al. Versatile cellular uptake mediated by catanionic vesicles: simultaneous spontaneous membrane fusion and endocytosis. Mol. Pharm. 12 (2015), 103–110, 10.1021/mp500458f.
63. Li, S., Fang, C., Zhang, J., Liu, B., Wei, Z., Fan, X., et al. Catanionic lipid nanosystems improve pharmacokinetics and anti-lung cancer activity of curcumin. Nanomedicine 12 (2016), 1567–1579, 10.1016/j.nano.2016.02.007.
64. Ndong Ntoutoume, G.M., Granet, R., Mbakidi, J.P., Brégier, F., Léger, D.Y., Fidanzi-Dugas, C., et al. Development of curcumin–cyclodextrin/cellulose nanocrystals complexes: new anticancer drug delivery systems. Bioorg. Med. Chem. Lett. 26 (2016), 941–945, 10.1016/j.bmcl.2015.12.060.
65. Soni, G., Yadav, K.S., Nanogels as potential nanomedicine carrier for treatment of cancer: a mini review of the state of the art. Saudi Pharm. J. 24 (2016), 133–139, 10.1016/j.jsps.2014.04.001.
66. Sarika, P.R., James, N.R., Kumar, P.R., Raj, D.K., Galactosylated alginate-curcumin micelles for enhanced delivery of curcumin to hepatocytes. Int. J. Biol. Macromol. 86 (2016), 1–9, 10.1016/j.ijbiomac.2016.01.037.
67. Das, R.K., Kasoju, N., Bora, U., Encapsulation of curcumin in alginate-chitosan-pluronic composite nanoparticles for delivery to cancer cells. Nanomedicine 6 (2010), 153–160, 10.1016/j.nano.2009.05.009.
68. Wiradharma, N., Zhang, Y., Venkataraman, S., Hedrick, J.L., Yang, Y.Y., Self-assembled polymer nanostructures for delivery of anticancer therapeutics. Nano Today 4 (2009), 302–317, 10.1016/j.nantod.2009.06.001.
69. Movassaghian, S., Merkel, O.M., Torchilin, V.P., Applications of polymer micelles for imaging and drug delivery. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 7 (2015), 691–707, 10.1002/wnan.1332.
70. Shi, Y., Lammers, T., Storm, G., Hennink, W.E., Physico-chemical strategies to enhance stability and drug retention of polymeric micelles for tumor-targeted drug delivery. Macromol. Biosci., 17, 2017, 16001160, 10.1002/mabi.201600160.
71. Gothwal, A., Khan, I., Gupta, U., Polymeric micelles: recent advancements in the delivery of anticancer drugs. Pharm. Res. 33 (2016), 18–39, 10.1007/s11095-015-1784-1.
72. Sahu, A., Kasoju, N., Bora, U., Fluorescence study of the curcumin-casein micelle complexation and its application as a drug nanocarrier to cancer cells. Biomacromolecules 9 (2008), 2905–2912, 10.1021/bm800683f.
73. Sahu, A., Bora, U., Kasoju, N., Goswami, P., Synthesis of novel biodegradable and self-assembling methoxy poly(ethylene glycol)-palmitate nanocarrier for curcumin delivery to cancer cells. Acta Biomater. 4 (2008), 1752–1761, 10.1016/j.actbio.2008.04.021.
74. Liu, L., Sun, L., Wu, Q., Guo, W., Li, L., Chen, Y., et al. Curcumin loaded polymeric micelles inhibit breast tumor growth and spontaneous pulmonary metastasis. Int. J. Pharm. 443 (2013), 175–182, 10.1016/j.ijpharm.2012.12.032.
75. Gong, C., Deng, S., Wu, Q., Xiang, M., Wei, X., Li, L., et al. Improving antiangiogenesis and anti-tumor activity of curcumin by biodegradable polymeric micelles. Biomaterials 34 (2013), 1413–1432, 10.1016/j.biomaterials.2012.10.068.
76. Gou, Q., Liu, L., Wang, C., Wu, Q., Sun, L., Yang, X., et al. Polymeric nanoassemblies entrapping curcumin overcome multidrug resistance in ovarian cancer. Colloids Surf. B Biointerfaces 126 (2015), 26–34, 10.1016/j.colsurfb.2014.12.012.
77. Petrov, P.D., Yoncheva, K., Gancheva, V., Konstantinov, S., Trzebicka, B., Multifunctional block copolymer nanocarriers for co-delivery of silver nanoparticles and curcumin: synthesis and enhanced efficacy against tumor cells. Eur. Polym. J. 81 (2016), 24–33, 10.1016/j.eurpolymj.2016.05.010.
78. Naksuriya, O., Shi, Y., van Nostrum, C.F., Anuchapreeda, S., Hennink, W.E., Okonogi, S., HPMA-based polymeric micelles for curcumin solubilization and inhibition of cancer cell growth. Eur. J. Pharm. Biopharm. 94 (2015), 501–512, 10.1016/j.ejpb.2015.06.010.
79. Liu, J., Xu, L., Liu, C., Zhang, D., Wang, S., Deng, Z., et al. Preparation and characterization of cationic curcumin nanoparticles for improvement of cellular uptake. Carbohydr. Polym. 90 (2012), 16–22, 10.1016/j.carbpol.2012.04.036.
80. Sajomsang, W., Gonil, P., Saesoo, S., Ruktanonchai, U.R., Srinuanchai, W., Puttipipatkhachorn, S., Synthesis and anticervical cancer activity of novel pH responsive micelles for oral curcumin delivery. Int. J. Pharm. 477 (2014), 261–272, 10.1016/j.ijpharm.2014.10.042.
81. Granja, S., Tavares-Valente, D., Queirós, O., Baltazar, F., Value of pH regulators in the diagnosis, prognosis and treatment of cancer. Semin Cancer Biol. 43 (2017), 17–34, 10.1016/j.semcancer.2016.12.003.
82. Fang, X.B., Zhang, J.M., Xie, X., Liuc, D., He, C.W., Wan, J.B., et al. pH-sensitive micelles based on acid-labile pluronic F68-curcumin conjugates for improved tumor intracellular drug delivery. Int. J. Pharm. 502 (2016), 28–37, 10.1016/j.ijpharm.2016.01.029.
83. Raveendran, R., Bhuvaneshwar, G.S., Sharma, C.P., Hemocompatible curcumin-dextran micelles as pH sensitivepro-drugs for enhanced therapeutic efficacy in cancer cells. Carbohydr. Polym. 137 (2016), 497–507, 10.1016/j.carbpol.2015.11.017.
84. Nagahama, K., Sano, Y., Kumano, T., Anticancer drug-based multifunctional nanogels through self-assembly of dextran-curcumin conjugates toward cancer theranostics. Bioorg. Med. Chem. Lett. 25 (2015), 2519–2522, 10.1016/j.bmcl.2015.04.062.
85. Wang, J., Wang, Y., Liu, Q., Yang, L., Zhu, R., Yu, C., et al. Rational design of multifunctional dendritic mesoporous silica nanoparticles to load curcumin and enhance efficacy for breast cancer therapy. ACS Appl. Mater. Interfaces, 8, 2016, 2651123, 10.1021/acsami.6b08400.
86. Phan, Q.T., Lec, M.H., Le, T.T., Tran, T.H., Xuan, P.N., Ha, P.T., Characteristics and cytotoxicity of folate-modified curcumin-loaded PLA-PEG micellar nano systems with various PLA:PEG ratios. Int. J. Pharm. 507 (2016), 32–40, 10.1016/j.ijpharm.2016.05.003.
87. Sarika, P.R., James, N.R., Kumar, P.R., Raj, D.K., Preparation, characterization and biological evaluation of curcumin loaded alginate aldehyde-gelatin nanogels. Mater. Sci. Eng. C 68 (2016), 251–257, 10.1016/j.msec.2016.05.046.
88. Yallapu, M.M., Khan, S., Maher, D.M., Ebeling, M.C., Sundram, V., Chauhan, N., et al. Anti-cancer activity of curcumin loaded nanoparticles in prostate cancer. Biomaterials 35 (2014), 8635–8648, 10.1016/j.biomaterials.2014.06.040.
89. Anirudhan, T.S., Binusreejayan Dextran based nanosized carrier for the controlled and targeted delivery of curcumin to liver cancer cells. Int. J. Biol. Macromol. 88 (2016), 222–235, 10.1016/j.ijbiomac.2016.03.040.
90. Mattarei, A., Azzolini, M., Carraro, M., Sassi, N., Zoratti, M., Paradisi, C., et al. Acetal derivatives as prodrugs of resveratrol. Mol. Pharm. 10 (2013), 2781–2789, 10.1021/mp400226p.
91. Jose, S., Anju, S.S., Cinu, T.A., Aleykutty, N.A., Thomas, S., Souto, E.B., In vivo pharmacokinetics and biodistribution of resveratrol-loaded. Int. J. Pharm. 474 (2014), 6–13, 10.1016/j.ijpharm.2014.08.003.
92. Soni, S., Ruhela, R.K., Medhi, B., Nanomedicine in central nervous system (CNS) disorders: a present and future prospective. Adv. Pharm. Bull. 6 (2016), 319–335, 10.15171/apb.2016.044.
93. Teskac, K., Kristl, J., The evidence for solid lipid nanoparticles mediated cell uptake of resveratrol. Int. J. Pharm. 390 (2010), 61–69, 10.1016/j.ijpharm.2009.10.011.
94. Jung, K.H., Lee, J.H., Park, J.W., Quach, C.H.T., Moon, S.H., Cho, Y.S., et al. Resveratrol-loaded polymeric nanoparticles suppress glucose metabolism and tumor growth in vitro and in vivo. Int. J. Pharm. 478 (2015), 251–257, 10.1016/j.ijpharm.2014.11.049.
95. Karthikeyan, S., Prasad, N.R., Ganamani, A., Balamurugan, E., Anticancer activity of resveratrol-loaded gelatin nanoparticles on NCI-H460 non-small cell lung cancer cells. Biomed. Prevent. Nutr. 3 (2013), 64–73.
96. Karthikeyan, S., Hoti, S.L., Prasad, N.R., Resveratrol loaded gelatin nanoparticles synergistically inhibits cell cycle progression and constitutive NF-kappaB activation, and induces apoptosis in non-small cell lung cancer cells. Biomed. Pharmacother. 70 (2015), 274–282, 10.1016/j.biopha.2015.02.006.
97. Sanna, V., Siddiqui, I.A., Sechi, M., Mukhtar, H., Resveratrol-loaded nanoparticles based on poly (epsilon-caprolactone) and poly (D,L-lactic-co-glycolic acid)-poly(ethylene glycol) blend for prostate cancer treatment. Mol. Pharm. 10 (2013), 3871–3881, 10.1021/mp400342f.
98. Summerlin, N., Qu, Z., Pujara, N., Sheng, Y., Jambhrunkar, S., McGuckin, M., et al. Colloidal mesoporous silica nanoparticles enhance the biologicalactivity of resveratrol. Colloids Surf. B Biointerfaces 144 (2016), 1–7, 10.1016/j.colsurfb.2016.03.076.
99. Carletto, B., Berton, J., Nascimento Ferreira, T., Facco Dalmolin, L., Paludo, K.S., Mainardes, R.M., et al. Resveratrol-loaded nanocapsules inhibit murine melanoma tumor growth. Colloids Surf. B 144 (2016), 65–72.
100. Guo, W., Li, A., Jia, Z., Yuan, Y., Dai, H., Li, H., Transferrin modified PEG-PLA-resveratrol conjugates: in vitro and in vivo studies for glioma. Eur. J. Pharmacol. 718 (2013), 41–47, 10.1016/j.ejphar.2013.09.034.
101. Zhao, Q.S., Hu, L., Wang, Z., Li, Z., Wang, A., Liue J Resveratrol-loaded folic acid-grafted dextran stearate submicron particles exhibits enhanced antitumor efficacy in non-small cell lung cancers. Mater. Sci. Eng. C Mater. Biol. Appl. 72 (2017), 185–191, 10.1016/j.msec.2016.10.077.
102. Bu, L., Gan, L.C., Guo, X.Q., Chen, F.Z., Song, Q.S., Zhao, Q., et al. Trans-resveratrol loaded chitosan nanoparticles modified with biotin and avidin to target hepatic carcinoma. Int. J. Pharm. 452 (2013), 355–362.
103. Liu, Y., Wu, Y.M., Yu, Y., Cao, C.S., Zhang, J.H., Li, K., et al. Curcumin and resveratrol in combination modulate drug metabolizing enzymes as well as antioxidant indices during lung carcinogenesis in mice. Hum. Exp. Toxicol. 34 (2015), 620–627, 10.1177/0960327114551396.
104. Saralkar, P., Dash, A.K., Alginate nanoparticles containing curcumin and resveratrol: preparation, characterization, and in vitro evaluation against DU145 prostate cancer cell line. AAPS PharmSciTech, 2017, 1–10, 10.1208/s12249-017-0772-7.
105. Caddeo, C., Nacher, A., Vassallo, A., Armentano, M.F., Pons, R., Fernàndez-Busquets, X., Carbone, C., Valenti, D., Fadda, A.M., Manconi, M., Effect of quercetin and resveratrol co-incorporated in liposomes against inflammatory/oxidative response associated with skin cancer. Int. J. Pharm. 513 (2016), 153–163, 10.1016/j.ijpharm.2016.09.014.
106. Zeng, X., Cai, D., Zeng, Q., Chen, Z., Zhong, G., Zhuo, J., et al. Selective reduction in the expression of UGTs and SULTs, a novel mechanism by which piperine enhances the bioavailability of curcumin in rat. Biopharm. Drug Dispos. 38 (2017), 3–19, 10.1002/bdd.2049.
107. Tang, J., Ji, H., Ren, J., Li, M., Zheng, N., Wu Solid lipid nanoparticles with TPGS and Brij 78: A co-delivery vehicle of curcumin and piperine for reversing P-glycoprotein-mediated multidrug resistance in vitro. Oncol Lett. 13 (2017), 389–395, 10.3892/ol.2016.5421.